Caliper and Seegene combine for diagnostic assays pact
This article was originally published in Clinica
Korean firm Seegene is to make its complete line of multiplex diagnostic assays available on Caliper Life Sciences’ LabChip Dx platform. Under the terms of the deal, the two companies will co-market the LabChip Dx platform as the system of choice for Seegene’s SeePlex assays outside of the US. The firms will also work together to expand the number of diagnostic tests available on the LabChip system. Caliper (Hopkinton, Massachusetts) says LabChip is a high-throughput, multiplex, sample-processing, microfluidic system that includes diagnostic identification, scoring and reporting software. It was developed in collaboration with Seoul-based Seegene. Seegene’s assays use dual priming oligonucleotide technology, which detects many pathogens in a single reaction and can be used on electrophoresis platforms. The assays test for a range of pathogens, and allow screening for respiratory diseases, human papillomavirus, Candida, sepsis, diarrhoea, meningitis, tuberculosis and STDs. Financial terms of the deal were not disclosed.